APO Research
Talk to an analyst

APO RESEARCH · REPORT

AL Amyloidosis Therapeutics

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global AL Amyloidosis Therapeutics Market Analysis and Forecast 2026-2032

21 December 2025190 pages

Choose your research edition.

Industry ResearchAL Amyloidosis Therapeutics Industry Research Report 2026117 pages · $2,950 USDIndustry Growth & TrendsGlobal AL Amyloidosis Therapeutics Industry Growth and Trends Forecast to 2032102 pages · $3,450 USDMarket StructureGlobal AL Amyloidosis Therapeutics Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032195 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal AL Amyloidosis Therapeutics Market Outlook and Growth Opportunities 2026193 pages · $4,250 USDMarket Analysis & ForecastGlobal AL Amyloidosis Therapeutics Market Analysis and Forecast 2026-2032190 pages · $4,950 USD

Market perspective

The global AL Amyloidosis Therapeutics market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for AL Amyloidosis Therapeutics is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for AL Amyloidosis Therapeutics is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for AL Amyloidosis Therapeutics is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for AL Amyloidosis Therapeutics is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of AL Amyloidosis Therapeutics include Janssen Pharmaceutical, Pfizer, GlaxoSmithKline Pharmaceuticals Ltd, Bristol-Myers Squibb, Spectrum Pharmaceuticals, Inc., Prothena, Oncopeptides AB, Eidos Therapeutics, Inc. and Corino Therapeutics, Inc., etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for AL Amyloidosis Therapeutics, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of AL Amyloidosis Therapeutics, also provides the revenue of main regions and countries. Of the upcoming market potential for AL Amyloidosis Therapeutics, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the AL Amyloidosis Therapeutics revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global AL Amyloidosis Therapeutics market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for AL Amyloidosis Therapeutics revenue, projected growth trends, production technology, application and end-user industry.

AL Amyloidosis Therapeutics Segment by Company

Janssen Pharmaceutical

Pfizer

GlaxoSmithKline Pharmaceuticals Ltd

Bristol-Myers Squibb

Spectrum Pharmaceuticals, Inc.

Prothena

Oncopeptides AB

Eidos Therapeutics, Inc.

Corino Therapeutics, Inc.

Alexion Pharmaceuticals

AL Amyloidosis Therapeutics Segment by Type

Chemotherapy

Supportive Care

Surgery

Stem Cell Transplant

Targeted Therapy

AL Amyloidosis Therapeutics Segment by Application

Clinics

Hospitals

Ambulatory Service Centres

Others

AL Amyloidosis Therapeutics Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global AL Amyloidosis Therapeutics market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of AL Amyloidosis Therapeutics and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of AL Amyloidosis Therapeutics.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of AL Amyloidosis Therapeutics in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of AL Amyloidosis Therapeutics company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, AL Amyloidosis Therapeutics revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global AL Amyloidosis Therapeutics Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Chemotherapy Major Player Table 3. Supportive Care Major Player Table 4. Surgery Major Player Table 5. Stem Cell Transplant Major Player Table 6. Targeted Therapy Major Player Table 7. Global AL Amyloidosis Therapeutics Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 8. Clinics Major Player Table 9. Hospitals Major Player Table 10. Ambulatory Service Centres Major Player Table 11. Others Major Player Table 12. AL Amyloidosis Therapeutics Industry Trends Table 13. AL Amyloidosis Therapeutics Industry Drivers Table 14. AL Amyloidosis Therapeutics Industry Opportunities and Challenges Table 15. AL Amyloidosis Therapeutics Industry Restraints Table 16. Global AL Amyloidosis Therapeutics Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 17. Global AL Amyloidosis Therapeutics Market Size by Region (2021-2026) & (US$ Million) Table 18. Global AL Amyloidosis Therapeutics Market Share by Region (2021-2026) Table 19. Global AL Amyloidosis Therapeutics Market Size by Region (2027-2032) & (US$ Million) Table 20. Global AL Amyloidosis Therapeutics Market Share by Region (2027-2032) Table 21. Global AL Amyloidosis Therapeutics Revenue by Players (US$ Million) & (2021-2026) Table 22. Global AL Amyloidosis Therapeutics Revenue Market Share by Players (2021-2026) Table 23. Global AL Amyloidosis Therapeutics Key Players Ranking, 2024 VS 2025 VS 2026 Table 24. Global AL Amyloidosis Therapeutics Key Players Headquarters & Area Served Table 25. Global AL Amyloidosis Therapeutics Players, Product Type & Application Table 26. Global AL Amyloidosis Therapeutics Players Establishment Date Table 27. Global Players Market Concentration Ratio (CR5 and HHI) Table 28. Global AL Amyloidosis Therapeutics by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 29. Global AL Amyloidosis Therapeutics Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 30. Global AL Amyloidosis Therapeutics Revenue by Type (2021-2026) & (US$ Million) Table 31. Global AL Amyloidosis Therapeutics Revenue by Type (2027-2032) & (US$ Million) Table 32. Global AL Amyloidosis Therapeutics Revenue Market Share by Type (2021-2026) Table 33. Global AL Amyloidosis Therapeutics Revenue Market Share by Type (2027-2032) Table 34. Global AL Amyloidosis Therapeutics Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 35. Global AL Amyloidosis Therapeutics Revenue by Application (2021-2026) & (US$ Million) Table 36. Global AL Amyloidosis Therapeutics Revenue by Application (2027-2032) & (US$ Million) Table 37. Global AL Amyloidosis Therapeutics Revenue Market Share by Application (2021-2026) Table 38. Global AL Amyloidosis Therapeutics Revenue Market Share by Application (2027-2032) Table 39. Janssen Pharmaceutical Company Information Table 40. Janssen Pharmaceutical Business Overview Table 41. Janssen Pharmaceutical AL Amyloidosis Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 42. Janssen Pharmaceutical AL Amyloidosis Therapeutics Product Portfolio Table 43. Janssen Pharmaceutical Recent Development Table 44. Pfizer Company Information Table 45. Pfizer Business Overview Table 46. Pfizer AL Amyloidosis Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 47. Pfizer AL Amyloidosis Therapeutics Product Portfolio Table 48. Pfizer Recent Development Table 49. GlaxoSmithKline Pharmaceuticals Ltd Company Information Table 50. GlaxoSmithKline Pharmaceuticals Ltd Business Overview Table 51. GlaxoSmithKline Pharmaceuticals Ltd AL Amyloidosis Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 52. GlaxoSmithKline Pharmaceuticals Ltd AL Amyloidosis Therapeutics Product Portfolio Table 53. GlaxoSmithKline Pharmaceuticals Ltd Recent Development Table 54. Bristol-Myers Squibb Company Information Table 55. Bristol-Myers Squibb Business Overview Table 56. Bristol-Myers Squibb AL Amyloidosis Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 57. Bristol-Myers Squibb AL Amyloidosis Therapeutics Product Portfolio Table 58. Bristol-Myers Squibb Recent Development Table 59. Spectrum Pharmaceuticals, Inc. Company Information Table 60. Spectrum Pharmaceuticals, Inc. Business Overview Table 61. Spectrum Pharmaceuticals, Inc. AL Amyloidosis Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 62. Spectrum Pharmaceuticals, Inc. AL Amyloidosis Therapeutics Product Portfolio Table 63. Spectrum Pharmaceuticals, Inc. Recent Development Table 64. Prothena Company Information Table 65. Prothena Business Overview Table 66. Prothena AL Amyloidosis Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 67. Prothena AL Amyloidosis Therapeutics Product Portfolio Table 68. Prothena Recent Development Table 69. Oncopeptides AB Company Information Table 70. Oncopeptides AB Business Overview Table 71. Oncopeptides AB AL Amyloidosis Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 72. Oncopeptides AB AL Amyloidosis Therapeutics Product Portfolio Table 73. Oncopeptides AB Recent Development Table 74. Eidos Therapeutics, Inc. Company Information Table 75. Eidos Therapeutics, Inc. Business Overview Table 76. Eidos Therapeutics, Inc. AL Amyloidosis Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 77. Eidos Therapeutics, Inc. AL Amyloidosis Therapeutics Product Portfolio Table 78. Eidos Therapeutics, Inc. Recent Development Table 79. Corino Therapeutics, Inc. Company Information Table 80. Corino Therapeutics, Inc. Business Overview Table 81. Corino Therapeutics, Inc. AL Amyloidosis Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 82. Corino Therapeutics, Inc. AL Amyloidosis Therapeutics Product Portfolio Table 83. Corino Therapeutics, Inc. Recent Development Table 84. Alexion Pharmaceuticals Company Information Table 85. Alexion Pharmaceuticals Business Overview Table 86. Alexion Pharmaceuticals AL Amyloidosis Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 87. Alexion Pharmaceuticals AL Amyloidosis Therapeutics Product Portfolio Table 88. Alexion Pharmaceuticals Recent Development Table 89. North America AL Amyloidosis Therapeutics Revenue by Type (2021-2026) & (US$ Million) Table 90. North America AL Amyloidosis Therapeutics Revenue by Type (2027-2032) & (US$ Million) Table 91. North America AL Amyloidosis Therapeutics Revenue by Application (2021-2026) & (US$ Million) Table 92. North America AL Amyloidosis Therapeutics Revenue by Application (2027-2032) & (US$ Million) Table 93. North America AL Amyloidosis Therapeutics Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 94. North America AL Amyloidosis Therapeutics Revenue by Country (2021-2026) & (US$ Million) Table 95. North America AL Amyloidosis Therapeutics Revenue by Country (US$ Million) & (2027-2032) Table 96. Europe AL Amyloidosis Therapeutics Revenue by Type (2021-2026) & (US$ Million) Table 97. Europe AL Amyloidosis Therapeutics Revenue by Type (2027-2032) & (US$ Million) Table 98. Europe AL Amyloidosis Therapeutics Revenue by Application (2021-2026) & (US$ Million) Table 99. Europe AL Amyloidosis Therapeutics Revenue by Application (2027-2032) & (US$ Million) Table 100. Europe AL Amyloidosis Therapeutics Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 101. Europe AL Amyloidosis Therapeutics Revenue by Country (2021-2026) & (US$ Million) Table 102. Europe AL Amyloidosis Therapeutics Revenue by Country (US$ Million) & (2027-2032) Table 103. China AL Amyloidosis Therapeutics Revenue by Type (2021-2026) & (US$ Million) Table 104. China AL Amyloidosis Therapeutics Revenue by Type (2027-2032) & (US$ Million) Table 105. China AL Amyloidosis Therapeutics Revenue by Application (2021-2026) & (US$ Million) Table 106. China AL Amyloidosis Therapeutics Revenue by Application (2027-2032) & (US$ Million) Table 107. Asia AL Amyloidosis Therapeutics Revenue by Type (2021-2026) & (US$ Million) Table 108. Asia AL Amyloidosis Therapeutics Revenue by Type (2027-2032) & (US$ Million) Table 109. Asia AL Amyloidosis Therapeutics Revenue by Application (2021-2026) & (US$ Million) Table 110. Asia AL Amyloidosis Therapeutics Revenue by Application (2027-2032) & (US$ Million) Table 111. Asia AL Amyloidosis Therapeutics Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 112. Asia AL Amyloidosis Therapeutics Revenue by Region (US$ Million) & (2021-2026) Table 113. Asia AL Amyloidosis Therapeutics Revenue by Region (US$ Million) & (2027-2032) Table 114. SAMEA AL Amyloidosis Therapeutics Revenue by Type (2021-2026) & (US$ Million) Table 115. SAMEA AL Amyloidosis Therapeutics Revenue by Type (2027-2032) & (US$ Million) Table 116. SAMEA AL Amyloidosis Therapeutics Revenue by Application (2021-2026) & (US$ Million) Table 117. SAMEA AL Amyloidosis Therapeutics Revenue by Application (2027-2032) & (US$ Million) Table 118. SAMEA AL Amyloidosis Therapeutics Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 119. SAMEA AL Amyloidosis Therapeutics Revenue by Country (2021-2026) & (US$ Million) Table 120. SAMEA AL Amyloidosis Therapeutics Revenue by Country (US$ Million) & (2027-2032) Table 121. Research Programs/Design for This Report Table 122. Authors List of This Report Table 123. Secondary Sources Table 124. Primary Sources List of Figures Figure 1. AL Amyloidosis Therapeutics Image Figure 2. Global AL Amyloidosis Therapeutics Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global AL Amyloidosis Therapeutics Market Size Share 2021 VS 2025 VS 2032 Figure 4. Chemotherapy Image Figure 5. Supportive Care Image Figure 6. Surgery Image Figure 7. Stem Cell Transplant Image Figure 8. Targeted Therapy Image Figure 9. Global AL Amyloidosis Therapeutics Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 10. Global AL Amyloidosis Therapeutics Market Size Share 2021 VS 2025 VS 2032 Figure 11. Clinics Image Figure 12. Hospitals Image Figure 13. Ambulatory Service Centres Image Figure 14. Others Image Figure 15. Global AL Amyloidosis Therapeutics Market Size (US$ Million) & (2021-2032) Figure 16. Global AL Amyloidosis Therapeutics Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 17. Global AL Amyloidosis Therapeutics Market Share by Region: 2021 VS 2025 VS 2032 Figure 18. Global AL Amyloidosis Therapeutics Players Revenue Share Top 10 and Top 5 in 2025 Figure 19. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 20. Global AL Amyloidosis Therapeutics Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 21. Global AL Amyloidosis Therapeutics Revenue Market Share 2021 VS 2025 VS 2032 Figure 22. Global AL Amyloidosis Therapeutics Revenue Market Share by Type (2021-2032) Figure 23. Global AL Amyloidosis Therapeutics Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 24. Global AL Amyloidosis Therapeutics Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 25. Global AL Amyloidosis Therapeutics Revenue Market Share by Application (2021-2032) Figure 26. North America AL Amyloidosis Therapeutics Revenue YoY Growth (2021-2032) & (US$ Million) Figure 27. North America AL Amyloidosis Therapeutics Revenue Share by Type (2021-2032) Figure 28. North America AL Amyloidosis Therapeutics Revenue Share by Application (2021-2032) Figure 29. North America AL Amyloidosis Therapeutics Revenue Share by Country (2021-2032) Figure 30. United States AL Amyloidosis Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 31. Canada AL Amyloidosis Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 32. Mexico AL Amyloidosis Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 33. Europe AL Amyloidosis Therapeutics Revenue YoY Growth (2021-2032) & (US$ Million) Figure 34. Europe AL Amyloidosis Therapeutics Revenue Share by Type (2021-2032) Figure 35. Europe AL Amyloidosis Therapeutics Revenue Share by Application (2021-2032) Figure 36. Europe AL Amyloidosis Therapeutics Revenue Share by Country (2021-2032) Figure 37. Germany AL Amyloidosis Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. France AL Amyloidosis Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. U.K. AL Amyloidosis Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Italy AL Amyloidosis Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Spain AL Amyloidosis Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. Russia AL Amyloidosis Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 43. Netherlands AL Amyloidosis Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 44. Nordic Countries AL Amyloidosis Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 45. China AL Amyloidosis Therapeutics Revenue YoY Growth (2021-2032) & (US$ Million) Figure 46. China AL Amyloidosis Therapeutics Revenue Share by Type (2021-2032) Figure 47. China AL Amyloidosis Therapeutics Revenue Share by Application (2021-2032) Figure 48. Asia AL Amyloidosis Therapeutics Revenue YoY Growth (2021-2032) & (US$ Million) Figure 49. Asia AL Amyloidosis Therapeutics Revenue Share by Type (2021-2032) Figure 50. Asia AL Amyloidosis Therapeutics Revenue Share by Application (2021-2032) Figure 51. Asia AL Amyloidosis Therapeutics Revenue Share by Region (2021-2032) Figure 52. Japan AL Amyloidosis Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. South Korea AL Amyloidosis Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. India AL Amyloidosis Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. Australia AL Amyloidosis Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 56. Taiwan AL Amyloidosis Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 57. Southeast Asia AL Amyloidosis Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 58. SAMEA AL Amyloidosis Therapeutics Revenue YoY Growth (2021-2032) & (US$ Million) Figure 59. SAMEA AL Amyloidosis Therapeutics Revenue Share by Type (2021-2032) Figure 60. SAMEA AL Amyloidosis Therapeutics Revenue Share by Application (2021-2032) Figure 61. SAMEA AL Amyloidosis Therapeutics Revenue Share by Country (2021-2032) Figure 62. Brazil AL Amyloidosis Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Argentina AL Amyloidosis Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Chile AL Amyloidosis Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Colombia AL Amyloidosis Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Peru AL Amyloidosis Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Saudi Arabia AL Amyloidosis Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Israel AL Amyloidosis Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. UAE AL Amyloidosis Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Turkey AL Amyloidosis Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 71. Iran AL Amyloidosis Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 72. Egypt AL Amyloidosis Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 73. Years Considered Figure 74. Research Process Figure 75. Key Executives Interviewed

Scope & coverage.

Types
  • Chemotherapy
  • Supportive Care
  • Surgery
  • Stem Cell Transplant
  • Targeted Therapy
Applications
  • Clinics
  • Hospitals
  • Ambulatory Service Centres
  • Others
Companies covered
  • Janssen Pharmaceutical
  • Pfizer
  • GlaxoSmithKline Pharmaceuticals Ltd
  • Bristol-Myers Squibb
  • Spectrum Pharmaceuticals, Inc.
  • Prothena
  • Oncopeptides AB
  • Eidos Therapeutics, Inc.
  • Corino Therapeutics, Inc.
  • Alexion Pharmaceuticals

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 AL Amyloidosis Therapeutics Market by Type
  3. 1.2.1 Global AL Amyloidosis Therapeutics Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Chemotherapy
  5. 1.2.3 Supportive Care
  6. 1.2.4 Surgery
  7. 1.2.5 Stem Cell Transplant
  8. 1.2.6 Targeted Therapy
  9. 1.3 AL Amyloidosis Therapeutics Market by Application
  10. 1.3.1 Global AL Amyloidosis Therapeutics Market Size by Application, 2021 VS 2025 VS 2032
  11. 1.3.2 Clinics
  12. 1.3.3 Hospitals
  13. 1.3.4 Ambulatory Service Centres
  14. 1.3.5 Others
  15. 1.4 Assumptions and Limitations
  16. 1.5 Study Goals and Objectives
2 AL Amyloidosis Therapeutics Market Dynamics
  1. 2.1 AL Amyloidosis Therapeutics Industry Trends
  2. 2.2 AL Amyloidosis Therapeutics Industry Drivers
  3. 2.3 AL Amyloidosis Therapeutics Industry Opportunities and Challenges
  4. 2.4 AL Amyloidosis Therapeutics Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global AL Amyloidosis Therapeutics Market Perspective (2021-2032)
  2. 3.2 Global AL Amyloidosis Therapeutics Growth Trends by Region
  3. 3.2.1 Global AL Amyloidosis Therapeutics Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global AL Amyloidosis Therapeutics Market Size by Region (2021-2026)
  5. 3.2.3 Global AL Amyloidosis Therapeutics Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global AL Amyloidosis Therapeutics Revenue by Players
  2. 4.1.1 Global AL Amyloidosis Therapeutics Revenue by Players (2021-2026)
  3. 4.1.2 Global AL Amyloidosis Therapeutics Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global AL Amyloidosis Therapeutics Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global AL Amyloidosis Therapeutics Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global AL Amyloidosis Therapeutics Key Players Headquarters & Area Served
  7. 4.4 Global AL Amyloidosis Therapeutics Players, Product Type & Application
  8. 4.5 Global AL Amyloidosis Therapeutics Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global AL Amyloidosis Therapeutics Market CR5 and HHI
  11. 4.6.3 2025 AL Amyloidosis Therapeutics Tier 1, Tier 2, and Tier 3
5 AL Amyloidosis Therapeutics Market Size by Type
  1. 5.1 Global AL Amyloidosis Therapeutics Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global AL Amyloidosis Therapeutics Revenue by Type (2021-2032)
  3. 5.3 Global AL Amyloidosis Therapeutics Revenue Market Share by Type (2021-2032)
6 AL Amyloidosis Therapeutics Market Size by Application
  1. 6.1 Global AL Amyloidosis Therapeutics Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global AL Amyloidosis Therapeutics Revenue by Application (2021-2032)
  3. 6.3 Global AL Amyloidosis Therapeutics Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Janssen Pharmaceutical
  2. 7.1.1 Janssen Pharmaceutical Company Information
  3. 7.1.2 Janssen Pharmaceutical Business Overview
  4. 7.1.3 Janssen Pharmaceutical AL Amyloidosis Therapeutics Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Janssen Pharmaceutical AL Amyloidosis Therapeutics Product Portfolio
  6. 7.1.5 Janssen Pharmaceutical Recent Developments
  7. 7.2 Pfizer
  8. 7.2.1 Pfizer Company Information
  9. 7.2.2 Pfizer Business Overview
  10. 7.2.3 Pfizer AL Amyloidosis Therapeutics Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Pfizer AL Amyloidosis Therapeutics Product Portfolio
  12. 7.2.5 Pfizer Recent Developments
  13. 7.3 GlaxoSmithKline Pharmaceuticals Ltd
  14. 7.3.1 GlaxoSmithKline Pharmaceuticals Ltd Company Information
  15. 7.3.2 GlaxoSmithKline Pharmaceuticals Ltd Business Overview
  16. 7.3.3 GlaxoSmithKline Pharmaceuticals Ltd AL Amyloidosis Therapeutics Revenue and Gross Margin (2021-2026)
  17. 7.3.4 GlaxoSmithKline Pharmaceuticals Ltd AL Amyloidosis Therapeutics Product Portfolio
  18. 7.3.5 GlaxoSmithKline Pharmaceuticals Ltd Recent Developments
  19. 7.4 Bristol-Myers Squibb
  20. 7.4.1 Bristol-Myers Squibb Company Information
  21. 7.4.2 Bristol-Myers Squibb Business Overview
  22. 7.4.3 Bristol-Myers Squibb AL Amyloidosis Therapeutics Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Bristol-Myers Squibb AL Amyloidosis Therapeutics Product Portfolio
  24. 7.4.5 Bristol-Myers Squibb Recent Developments
  25. 7.5 Spectrum Pharmaceuticals, Inc.
  26. 7.5.1 Spectrum Pharmaceuticals, Inc. Company Information
  27. 7.5.2 Spectrum Pharmaceuticals, Inc. Business Overview
  28. 7.5.3 Spectrum Pharmaceuticals, Inc. AL Amyloidosis Therapeutics Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Spectrum Pharmaceuticals, Inc. AL Amyloidosis Therapeutics Product Portfolio
  30. 7.5.5 Spectrum Pharmaceuticals, Inc. Recent Developments
  31. 7.6 Prothena
  32. 7.6.1 Prothena Company Information
  33. 7.6.2 Prothena Business Overview
  34. 7.6.3 Prothena AL Amyloidosis Therapeutics Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Prothena AL Amyloidosis Therapeutics Product Portfolio
  36. 7.6.5 Prothena Recent Developments
  37. 7.7 Oncopeptides AB
  38. 7.7.1 Oncopeptides AB Company Information
  39. 7.7.2 Oncopeptides AB Business Overview
  40. 7.7.3 Oncopeptides AB AL Amyloidosis Therapeutics Revenue and Gross Margin (2021-2026)
  41. 7.7.4 Oncopeptides AB AL Amyloidosis Therapeutics Product Portfolio
  42. 7.7.5 Oncopeptides AB Recent Developments
  43. 7.8 Eidos Therapeutics, Inc.
  44. 7.8.1 Eidos Therapeutics, Inc. Company Information
  45. 7.8.2 Eidos Therapeutics, Inc. Business Overview
  46. 7.8.3 Eidos Therapeutics, Inc. AL Amyloidosis Therapeutics Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Eidos Therapeutics, Inc. AL Amyloidosis Therapeutics Product Portfolio
  48. 7.8.5 Eidos Therapeutics, Inc. Recent Developments
  49. 7.9 Corino Therapeutics, Inc.
  50. 7.9.1 Corino Therapeutics, Inc. Company Information
  51. 7.9.2 Corino Therapeutics, Inc. Business Overview
  52. 7.9.3 Corino Therapeutics, Inc. AL Amyloidosis Therapeutics Revenue and Gross Margin (2021-2026)
  53. 7.9.4 Corino Therapeutics, Inc. AL Amyloidosis Therapeutics Product Portfolio
  54. 7.9.5 Corino Therapeutics, Inc. Recent Developments
  55. 7.10 Alexion Pharmaceuticals
  56. 7.10.1 Alexion Pharmaceuticals Company Information
  57. 7.10.2 Alexion Pharmaceuticals Business Overview
  58. 7.10.3 Alexion Pharmaceuticals AL Amyloidosis Therapeutics Revenue and Gross Margin (2021-2026)
  59. 7.10.4 Alexion Pharmaceuticals AL Amyloidosis Therapeutics Product Portfolio
  60. 7.10.5 Alexion Pharmaceuticals Recent Developments
8 North America
  1. 8.1 North America AL Amyloidosis Therapeutics Revenue (2021-2032)
  2. 8.2 North America AL Amyloidosis Therapeutics Revenue by Type (2021-2032)
  3. 8.2.1 North America AL Amyloidosis Therapeutics Revenue by Type (2021-2026)
  4. 8.2.2 North America AL Amyloidosis Therapeutics Revenue by Type (2027-2032)
  5. 8.3 North America AL Amyloidosis Therapeutics Revenue Share by Type (2021-2032)
  6. 8.4 North America AL Amyloidosis Therapeutics Revenue by Application (2021-2032)
  7. 8.4.1 North America AL Amyloidosis Therapeutics Revenue by Application (2021-2026)
  8. 8.4.2 North America AL Amyloidosis Therapeutics Revenue by Application (2027-2032)
  9. 8.5 North America AL Amyloidosis Therapeutics Revenue Share by Application (2021-2032)
  10. 8.6 North America AL Amyloidosis Therapeutics Revenue by Country
  11. 8.6.1 North America AL Amyloidosis Therapeutics Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America AL Amyloidosis Therapeutics Revenue by Country (2021-2026)
  13. 8.6.3 North America AL Amyloidosis Therapeutics Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe AL Amyloidosis Therapeutics Revenue (2021-2032)
  2. 9.2 Europe AL Amyloidosis Therapeutics Revenue by Type (2021-2032)
  3. 9.2.1 Europe AL Amyloidosis Therapeutics Revenue by Type (2021-2026)
  4. 9.2.2 Europe AL Amyloidosis Therapeutics Revenue by Type (2027-2032)
  5. 9.3 Europe AL Amyloidosis Therapeutics Revenue Share by Type (2021-2032)
  6. 9.4 Europe AL Amyloidosis Therapeutics Revenue by Application (2021-2032)
  7. 9.4.1 Europe AL Amyloidosis Therapeutics Revenue by Application (2021-2026)
  8. 9.4.2 Europe AL Amyloidosis Therapeutics Revenue by Application (2027-2032)
  9. 9.5 Europe AL Amyloidosis Therapeutics Revenue Share by Application (2021-2032)
  10. 9.6 Europe AL Amyloidosis Therapeutics Revenue by Country
  11. 9.6.1 Europe AL Amyloidosis Therapeutics Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe AL Amyloidosis Therapeutics Revenue by Country (2021-2026)
  13. 9.6.3 Europe AL Amyloidosis Therapeutics Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China AL Amyloidosis Therapeutics Revenue (2021-2032)
  2. 10.2 China AL Amyloidosis Therapeutics Revenue by Type (2021-2032)
  3. 10.2.1 China AL Amyloidosis Therapeutics Revenue by Type (2021-2026)
  4. 10.2.2 China AL Amyloidosis Therapeutics Revenue by Type (2027-2032)
  5. 10.3 China AL Amyloidosis Therapeutics Revenue Share by Type (2021-2032)
  6. 10.4 China AL Amyloidosis Therapeutics Revenue by Application (2021-2032)
  7. 10.4.1 China AL Amyloidosis Therapeutics Revenue by Application (2021-2026)
  8. 10.4.2 China AL Amyloidosis Therapeutics Revenue by Application (2027-2032)
  9. 10.5 China AL Amyloidosis Therapeutics Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia AL Amyloidosis Therapeutics Revenue (2021-2032)
  2. 11.2 Asia AL Amyloidosis Therapeutics Revenue by Type (2021-2032)
  3. 11.2.1 Asia AL Amyloidosis Therapeutics Revenue by Type (2021-2026)
  4. 11.2.2 Asia AL Amyloidosis Therapeutics Revenue by Type (2027-2032)
  5. 11.3 Asia AL Amyloidosis Therapeutics Revenue Share by Type (2021-2032)
  6. 11.4 Asia AL Amyloidosis Therapeutics Revenue by Application (2021-2032)
  7. 11.4.1 Asia AL Amyloidosis Therapeutics Revenue by Application (2021-2026)
  8. 11.4.2 Asia AL Amyloidosis Therapeutics Revenue by Application (2027-2032)
  9. 11.5 Asia AL Amyloidosis Therapeutics Revenue Share by Application (2021-2032)
  10. 11.6 Asia AL Amyloidosis Therapeutics Revenue by Country
  11. 11.6.1 Asia AL Amyloidosis Therapeutics Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia AL Amyloidosis Therapeutics Revenue by Country (2021-2026)
  13. 11.6.3 Asia AL Amyloidosis Therapeutics Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA AL Amyloidosis Therapeutics Revenue (2021-2032)
  2. 12.2 SAMEA AL Amyloidosis Therapeutics Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA AL Amyloidosis Therapeutics Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA AL Amyloidosis Therapeutics Revenue by Type (2027-2032)
  5. 12.3 SAMEA AL Amyloidosis Therapeutics Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA AL Amyloidosis Therapeutics Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA AL Amyloidosis Therapeutics Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA AL Amyloidosis Therapeutics Revenue by Application (2027-2032)
  9. 12.5 SAMEA AL Amyloidosis Therapeutics Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA AL Amyloidosis Therapeutics Revenue by Country
  11. 12.6.1 SAMEA AL Amyloidosis Therapeutics Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA AL Amyloidosis Therapeutics Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA AL Amyloidosis Therapeutics Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst